Schizophrenia (SCZ) and major depressive disorder (MDD) in treatment‐naive patients are
associated with increased risk for type 2 diabetes (T2D) and metabolic syndrome (MetS) …

Objectives To systematically review findings of GWAS in schizophrenia (SZ) and in bipolar
disorder (BD); and to interpret findings, with a focus on identifying independent replications …

The major histocompatibility complex (MHC) is one of the most intensively investigated,
genetically diverse regions of the genome. In its extended form, it encodes more than 400 …

Schizophrenia is a severe psychiatric disease with inflammatory component. Several studies
indicated the increased blood levels of proinflammatory interleukin‐6 cytokine in …

Background In schizophrenia, genetic background may provide a substrate for intrinsic
maldevelopment of the brain through environmental influences, by recruiting neurotrophic …

Many reports in different populations have demonstrated linkage of the 10q24–q26 region to
schizophrenia, thus encouraging further analysis of this locus for detection of specific …

Schizophrenia is a disease affecting up to 1% of the population. Current therapies are based
on the efficacy of chlorpromazine, discovered over 50 years ago. These drugs block …

Genes that are differentially expressed between schizophrenia patients and healthy controls
may have key roles in the pathogenesis of schizophrenia. We analyzed two large-scale …

Background Genome-wide association studies (GWAS) have identified several loci
associated with schizophrenia and/or bipolar disorder. We performed a GWAS of psychosis …

Background: Genome-wide association studies have been extensively applied in identifying
SNP associated with major psychiatric disorders. However, the SNPs identified by the …